AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

STIM · NASDAQ · Medical - Devices

Neuronetics

Sells NeuroStar TMS systems and operates Greenbrook mental-health treatment centers.

$2.97

After-hours close+0.03 (+0.89%)

At close$2.94(−0.68%)

Something off on this page? Send us feedback.

Profile

Neuronetics, Inc.STIMHealth Care

Sells NeuroStar TMS systems, recurring treatment sessions, and direct clinic services for depression-related care. The Greenbrook acquisition shifted the model into medical device and clinic services segments, with operations concentrated in the United States.

Sells and supports the NeuroStar Advanced Therapy System, a transcranial magnetic stimulation platform used for major depressive disorder and related mental-health indications. Revenue comes from system placements, recurring treatment sessions, service and support, and Greenbrook clinic services.

Operates mostly in the United States after the Greenbrook acquisition, which added company-operated treatment centers and shifted the business into a vertically integrated model. Medical device and clinic services are now the reported operating segments.

Execution depends on provider adoption, clinic utilization, FDA-cleared indications, and third-party insurance coverage for treatments using its products and services.

Company facts

CEODan Reuvers

ListedJun 28, 2018

ExchangeNASDAQ

HeadquartersMalvern, PA

CountryUnited States

Employees658

CIK0001227636

ISINUS64131A1051

Key statistics

Market cap$204.6M

EPS (ttm)−$0.4300

P/E (ttm)−6.84

ROE-150.6%

P/B11.75

P/S1.32

Dividend yield—

Beta2.18vs XLV 0.39

Year to date +104% · Average volume (30d) 2.6M

Analysts

Price target, next 12 months$5.00+70.1%Median of 7 analysts · vs the Aug 28 close

ConsensusBuy6 of 7 analysts rate it buy or better

Ratings

Strong buyBuyHoldSellStrong sell

Target range

Last close $2.94

High$5.00+70.1%

Median$5.00+70.1%

Low$5.00+70.1%

12 months agoNowIn 12 months

Latest analyst notes

Date	Firm	Action	Rating	Target
Jul 20, 2026	BTIG	Initiate	Buy	$5

Earnings

EPS

Estimate−$0.09

ReportedDue Nov 3, 2026

Revenue

Estimate$40.3M

ReportedDue Nov 3, 2026

History

Report date	EPS est	EPS	Surprise	Revenue est	Revenue	Surprise	Next session
Aug 11, 2026Q2 FY26	−$0.12	−$0.05	+59.3%	$40.2M	$41.6M	+3.5%	+47.00%
May 5, 2026Q1 FY26	−$0.17	−$0.16	+5.9%	$34.2M	$34.5M	+0.8%	−11.98%
Mar 17, 2026Q4 FY25	−$0.12	−$0.10	+16.7%	$40.7M	$41.8M	+2.7%	+9.76%
Nov 4, 2025Q3 FY25	−$0.12	−$0.13	−8.3%	$37.8M	$37.3M	−1.5%	−4.53%

View details

Financial highlights

	Q1 FY25	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26
Revenue	$32.0M	$38.1M	$37.3M	$41.8M	$34.5M	$41.6M
Gross profit	$15.7M	$17.8M	$17.1M	$21.7M	$16.2M	$21.2M
Operating income	−$11.0M	−$8.1M	−$7.3M	−$5.0M	−$9.0M	−$1.5M
Net income	−$12.7M	−$10.1M	−$9.0M	−$7.2M	−$10.8M	−$3.4M
Diluted EPS	−$0.21	−$0.15	−$0.13	−$0.10	−$0.16	−$0.04
Gross margin	49.2%	46.6%	45.9%	52.0%	46.9%	51.1%
Operating margin	-34.4%	-21.1%	-19.6%	-12.1%	-26.1%	-3.6%

Fiscal years (4-quarter sums)FY21 $55.3M · FY22 $65.2M · FY23 $71.3M · FY24 $74.9M · FY25 $149.2M

Revenue by product · Q2 FY26

Service$26.9M · 65%

Product$14.7M · 35%

Revenue by geography · Q2 FY26

Non-US$1.0M · 100%

Balance sheet, Jun 30, 2026Cash & short-term investments $19.4M · Total debt $86.5M · Total assets $131.5M · Shareholders' equity $17.9M

Dividends

No dividends on record.

Ownership

Institutions 59.85%41.65M sharesInsiders 13.57%9.44M sharesOther 26.58%18.50M shares

Shares outstanding 69.59M · Float 28.29M · 40.7% free float

Top shareholders13F · 13D/G · Form 4

Holder	Shares	% outstanding	Form	Filed
Chernett Jorey	10.60M	13.92%	13D	Aug 24, 2026
Parian Ultreia LP	4.84M	7.00%	13G	Mar 17, 2026
Point72 Asset Management, L.P.	3.82M	5.00%	13G	Aug 14, 2026
UBS Group AG	2.87M	4.13%	13F	May 5, 2026
Balyasny Asset Management L.P.	2.74M	3.94%	13F	May 15, 2026

Insider tradesForm 4

Date	Insider	Role	Shares	Avg price
Aug 13, 2026	Jorey Chernett	10 percent owner	−100	$5.00
Aug 14, 2026	Jorey Chernett	10 percent owner	+14,000	$3.16
Jul 14, 2026	Jorey Chernett	10 percent owner	+35,000	$1.78
Mar 19, 2026	Steven Pfanstiel	officer: Former EVP, CFO and Treasurer	−25,000	$1.34
May 19, 2026	Jorey Chernett	10 percent owner	+100,000	$1.17